You just read:

Significant Improvement in Progression-Free Survival With Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer: Data Confirmed in New Subgroup Analyses

News provided by

Eisai Europe Limited

06 Sep, 2014, 23:01 BST